Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Johnson & Johnson (NYSE:JNJ)

118.86
Delayed Data
As of Feb 17
 +0.78 / +0.66%
Today’s Change
102.23
Today|||52-Week Range
126.07
+3.17%
Year-to-Date
JNJ Regular Dividend: JNJ will begin trading ex-dividend on 02/24/17 with a $0.80 dividend payable to shareholders of record as of 02/28/17.
3 Stocks to Invest in Big Pharma
Feb 20 / MotleyFool.com - Paid Partner Content
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ
Feb 17 / Zacks.com - Paid Partner Content
Better Buy: Eli Lilly and Company vs. Johnson & Johnson
Feb 18 / MotleyFool.com - Paid Partner Content
Glg Llc Buys Midstates Petroleum Co, Apple, Johnson & Johnson, Sells Teva Pharmaceuti...
Feb 16 / GuruFocus News - Paid Partner Content
The Four Key Themes From Q4 Conference Calls
Feb 17 / Investing Channel - Paid Partner Content
Hurry Up and Grab Some Johnson & Johnson Before the Stock Bursts Even More
Feb 16 / TheStreet.com - Paid Partner Content
Geron (GERN) Q4 Earnings: What's in Store for the Stock?
Feb 17 / Zacks.com - Paid Partner Content
How Bristol-Myers Squibb and Pfizer Are Winning a Big Brawl in Blood Thinners
Feb 16 / MotleyFool.com - Paid Partner Content
Pfizer's Xeljanz Combo Comparable to AbbVie's Humira
Feb 17 / Zacks.com - Paid Partner Content
Health Care ETF Has Been Ailing
Feb 16 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close118.08
Today’s open118.19
Day’s range118.05 - 118.90
Volume8,691,397
Average volume (3 months)7,152,849
Market cap$323.4B
Dividend yield2.69%
Data as of 02/17/2017

Growth & Valuation

Earnings growth (last year)+8.21%
Earnings growth (this year)+4.73%
Earnings growth (next 5 years)+6.00%
Revenue growth (last year)+2.41%
P/E ratio20.9
Price/Sales4.47
Price/Book--

Competitors

 Today’s
change
Today’s
% change
PFEPfizer0.000.00%
MRKMerck+0.13+0.20%
NVSNovartis+0.47+0.61%
SNYSanofi-0.38-0.87%
Data as of 4:02pm ET, 02/17/2017

Financials

Next reporting dateApril 18, 2017
EPS forecast (this quarter)$1.76
Annual revenue (last year)$71.9B
Annual profit (last year)$16.5B
Net profit margin23.01%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chairman &
Chief Executive Officer
Alex Gorsky
Chief Financial Officer &
Vice President
Dominic J. Caruso
Corporate headquarters
New Brunswick, New Jersey

Forecasts


Search for Jobs